[Federal Register Volume 59, Number 232 (Monday, December 5, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-29746]
[[Page Unknown]]
[Federal Register: December 5, 1994]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
The inventions listed below are owned by agencies of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for U.S. companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by contacting Leopold J.
Luberecki, Jr., J.D., Technology Licensing Specialist, Office of
Technology Transfer, National Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, Maryland 20852-3804 (telephone 301/
496-7735 ext. 223; fax 301/402-0220). A signed Confidential Disclosure
Agreement will be required to receive copies of the patent
applications. Issued patents may be obtained from the Commissioner of
Patents, U.S. Patent and Trademark Office, Washington, DC 20231.
Recombinant Vaccinia Virus Encoding Cytochromes P-450
Gelboin, H.V., Battula, N., Gonzalez, F.J., Moss, B. (NCI, NIAID)
Serial No. 07/787,777 filed 6 Nov 91
U.S. Patent 5,164,313 issued 17 Nov 92
Serial No. 08/166,287
Filed 13 Dec 93 [FWC of 07/930,781 (Aban), which is DIV of 07/787,777]
This invention describes the construction and uses of recombinant
vaccinia viruses containing DNA sequences that express enzymatically
active cytochromes P1-450 and P3-450 in mammalian cells without
requiring the extraneous addition of NADPH cytochrome P450 reductase or
cell fractions for catalytic activity. This novel recombinant virus can
be used to evaluate the cytochrome P-450-mediated metabolism and
mutagenicity of xenobiotic or endobiotic compounds and chemical agents.
The invention represents the first expression of cytochrome P-450 in a
variety of mammalian systems using infectious viruses.
Chemotherapeutic Agent Evaluation Using Cells Grown In Hollow Fibers In
Vivo
Hollingshead, M.G. (NCI)
Filed 5 May 93
Serial No. 08/058,154
A novel method has been developed to quickly evaluate and screen
potential anti-cancer and anti-viral drugs in vivo. The desire for
effective treatments for tumors and viral infections has created a need
in the research and medical communities for a quick, reliable way to
test chemotherapeutic agents. Although several teams of investigators
have attempted in recent years to develop in vivo methods for screening
such drugs, these methods have had limited value because they usually
permit only the agent to be tested against one type of tumor cell or
cell line per experiment and/or have been labor intensive and
expensive. This new method for screening chemotherapeutic agents
involves encapsulating the target (i.e., tumor) cells in a
biocompatible, semipermeable membrane--which is made of unique hollow
fibers or dialysis tubing--and transplanting the encapsulated cells
into a laboratory animal. Each laboratory animal can receive an implant
at a single site or multiple sites, making it possible to test a
chemotherapeutic agent against several types of tumor cells
simultaneously. The membrane, which does not generate an autoimmune
response or release any toxic chemicals, allows for the target cells to
be reharvested after the treatment.
Sensitive Method For Locating Chromosomal Breakpoints
Magrath, I.T., Shiramizu, B. (NCI)
Filed 2 Dec 93
Serial No. 08/160,547 (CON of 07/698,233, CON of 07/441,516)
A new technique for localizing chromosomal breakpoints offers a
significant advancement in detecting genetic translocations such as
those found in Burkitt's lymphoma. Present techniques for detecting
chromosomal breakpoints require large amounts of tumor sample, are
often insensitive, or are cumbersome and time consuming. This new
technique utilizes sequence-specific primers for rapid, efficient PCR
amplification of a fragment containing a breakpoint. This technique is
so sensitive it can be used to sub-divide Burkitt's lymphomas into
subtypes based on the location of chromosomal breakpoints.
Method For Estimating mRNA Content By Filter Hybridization To A
Polythymidylate Probe
Hollander, M.C., Fornace, A.J. (NCI)
Filed 21 Feb 94
Serial No. 08/183,911 (CON of 07/908,814, CON of 07/501,774)
A method for the quantitation of relative mRNA samples which
entails hybridization of a polythymidylate (polyT) probe with RNA bound
to an insoluble substrate. This method is especially applicable for
normalizing numerous RNA samples which are to be analyzed by dot blot
hybridization. The relative hybridization of polyT probe to RNA is
proportional to the polyA RNA content of the RNA samples. Since the
hybridization of polyT probe to RNA does not appear to be dependent on
any cell treatment or growth condition and experimental variation is
minimized, this method is a better method for standardizing the amount
of mRNA in RNA samples than is relative hybridization to cDNA probes
such as actin or 2-microglobulin, the transcript levels
of which may vary according to cell treatment.
Sphingoid Bases And Methods For Their Preparation And Use
Boumendjel, A., Miller, S.P.F. (NINDS)
Filed 14 Feb 94
Serial No. 08/195,815
This is a new method for synthesizing a group of novel analogs of
sphingosine-1-phosphate (S-1-P) that offer improved methods of studying
cell growth as well as other cell regulatory processes. Sphingolipids
compromise a large class of biologically significant compounds, some of
which act upon enzymes that control cell growth or have potent mitogen
activity. Previously, it has been difficult to study this class of
compounds because there was no economically feasible method of
producing large-scale amounts; however, a method has been developed for
synthesizing S-1-P and other related analogs with greater yields and
quantities in a shorter period of time compared to previous methods,
allowing for large-scale production of these compounds at much lower
costs.
A Novel Chaperone Protein
Kaye, F.J., Otterson, G.A. (NCI)
Filed 28 Feb 94
Serial No. 08/203,905
The gene sequences for the rat and human Stch chaperone protein,
which belongs to the heat shock protein (HSP) family, have been
isolated and characterized. HSP products have been localized to
specific cellular fractions, such as cytosol, nucleus, endoplasmic
reticulum, and mitochondria, and recent experimental models have
implicated these ``chaperones'' in facilitating protein transport
across these specialized compartments. The Stch protein has significant
differences from previously identified heat shock proteins and is
expressed in tumor origin cells. These novel gene sequences and probes
derived from the gene sequences are useful for quantitating the amount
of Stch gene transcript in tissues, and antibodies are useful for
detecting the presence of protein in cells.
Genes Coding For Melanoma Tumor Antigens
Kawakami, Y., Rosenberg, S.A. (NCI)
Filed 22 Apr 94
Serial No. 08/231,565
Genes have been isolated that code for melanoma tumor antigens,
which may provide an important new method for the prevention or
treatment of this deadly form of cancer. Melanomas are aggressive,
frequently metastatic tumors, and even when the melanoma is apparently
localized to the skin, up to 30 percent of patients eventually will
have the tumor spread to other organs and tissues of the body. The
majority of these individuals will die. Recent studies have shown that
many melanoma patients mount cellular and humoral responses against
these tumors and that melanomas express both MHC antigens and tumor-
associated antigens. These newly discovered melanoma antigen genes may
be used in gene therapy protocols, or peptides derived from the gene
product may be used in vaccines to help the recipient mount a T-cell-
mediated immune response against the melanoma.
Dated: November 16, 1994.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 94-29746 Filed 12-2-94; 8:45 am]
BILLING CODE 4140-01-P
